Ethylene Oxide (EtO) Lawsuit Update (July 2026)

Why Ethylene Oxide Belongs on Your Docket Review Right Now

Ethylene oxide mass tort marketing has emerged as one of the higher-conviction acquisition plays available to plaintiff firms in 2026, anchored by the $408 million Sterigenics settlement and a growing docket of active cases against Medline Industries, Becton Dickinson, and STERIS. The science is settled, the claimant geography is mappable, and bellwether verdicts have already demonstrated jury willingness to hold industrial emitters accountable. For firms evaluating where to deploy intake budget over the next 12 to 24 months, EtO presents a documented track record, not a speculative position.

The question is not whether the cases have value. The Kamuda verdict and the subsequent global settlement answered that. The real question is whether you can build a cost-effective acquisition pipeline now, before trial momentum in the Medline and BD cases does what it always does: drives up lead prices and reduces the window for early-mover economics.

The Litigation Landscape and What It Means for Acquisition Timing

Start with the scoreboard. In 2022, a Cook County jury awarded Susan Kamuda $363 million against Sterigenics. That verdict sent a clear signal about jury sentiment in communities living near EtO sterilization facilities. Sterigenics then settled the broader Willowbrook group for $408 million in 2023, establishing per-case benchmarks that have since anchored valuation conversations for every EtO case that follows.

The Willowbrook chapter is closed. What is open now are the cases tied to other facilities. Medline Industries operates a sterilization plant in Waukegan, Illinois, a densely populated community north of Chicago. Becton Dickinson faces claims in Covington, Georgia, just outside Atlanta, and in other Georgia facilities. STERIS is an emerging defendant in Laredo, Texas. These are active litigation streams with real plaintiff populations and defendants that have the balance sheets to fund substantial settlements.

The docket sits in N.D. Illinois under coordinated, though not formally MDL-designated, consolidation. With 2,000-plus active plaintiffs already and a filing trend that continues to grow, the case volume is real. Bellwether trials against the next-wave defendants are working through scheduling, and the Kamuda precedent gives plaintiffs' counsel significant leverage in those discussions. For acquisition strategy, the implication is straightforward: you are still in the period where cases can be signed before trial results in the Medline and BD proceedings create a new pricing floor. That window is not permanent.

The Claimant Pool, Saturation, and Where Volume Still Exists

One of the reasons EtO is attractive from a firm economics standpoint is the precision of the geographic exposure model. Cases are not drawn from a national consumer pool. Eligibility requires proximity, specifically, documented residence or work within roughly one to three miles of an identified sterilization facility for at least one year, combined with a qualifying cancer diagnosis, primarily breast cancer or non-Hodgkin lymphoma.

That precision cuts both ways. It limits total addressable volume compared to a national pharmaceutical tort, but it also means your media spend goes to defined ZIP codes rather than a broad national scatter. You are not competing for the same audience as every other plaintiff firm in the country. You are competing for a specific, locatable population in places like Waukegan, Covington, and Laredo.

Willowbrook has been largely worked. The Sterigenics settlement processed that community's claims. The remaining addressable pool is concentrated in the active facility locations. Waukegan is the largest remaining urban cluster. The Atlanta-area and Covington geography tied to BD is significant given the metro population density. Laredo is earlier stage and less saturated. Firms willing to invest in geographic-specific campaigns against these communities are not walking into a saturated market. Saturation is a problem for national pharmaceutical torts with three years of television advertising behind them. EtO does not have that problem yet.

Ethylene Oxide Mass tort Marketing: Acquisition Economics and Channel Strategy

Ethylene oxide mass tort marketing operates differently from broad-reach pharmaceutical campaigns. Because the qualifying population is defined by geography and a specific cancer diagnosis, channel selection and creative targeting need to reflect that reality.

Facebook and Meta remain the workhorse channel for this tort. Geofenced campaigns targeting ZIP codes within the exposure radius, layered with interest and demographic signals relevant to cancer survivors and caregivers, produce the most cost-efficient lead volume. Display and programmatic can supplement, particularly for retargeting. Broadcast television is generally inefficient for this tort because the qualifying audience is too geographically concentrated to justify the CPM waste across a full market buy.

On cost: realistic cost-per-lead ranges for EtO currently sit in the $80 to $180 range depending on geography, creative, and how aggressively you are targeting. Cost per signed retainer typically runs $600 to $1,500 for well-run campaigns with strong intake processes behind them. Those numbers will move upward as more firms enter the space and as trial results create urgency in the market, which is another argument for moving sooner rather than later.

Creative angles that convert tend to lean on the EPA and IARC carcinogen classifications (this is not a "we allege it caused harm" tort, it is a "the EPA says it is a definite human carcinogen" tort), combined with the specific facility geography. Mentioning the Sterigenics settlement in creative builds credibility and communicates that these cases have real value. Localized creative referencing Waukegan, Covington, or Laredo specifically performs better than generic EtO messaging because it helps the right people self-identify.

Intake and Qualification: Building a Pipeline That Holds

Intake for EtO cases requires two verification steps that not every tort demands. First, proximity. Your intake team needs to confirm that the claimant lived or worked within the documented exposure zone for the required duration. This means having address ranges and ZIP code maps for each facility built into your intake script from day one. Do not rely on the claimant's self-assessment. Run the address against your exposure data during the intake call.

Second, the cancer diagnosis. Breast cancer and non-Hodgkin lymphoma are the primary qualifying injuries, supported by the strongest causation science. Other EtO-linked cancers exist but carry more causation complexity. Build your intake criteria around your retained experts' comfort zone on injury type before you start spending on acquisition. Signing cases your experts will not support is expensive.

Medical record retrieval should start immediately after retainer execution. Cases that stall at records retrieval are dead weight on your docket. Build an automated follow-up sequence for records requests, whether through your case management software, a dedicated intake vendor, or an AI-assisted workflow. Firms using AI tools for intake automation and records tracking are seeing real reductions in time-to-qualified and time-to-filed. If your firm has not evaluated those tools yet, that operational gap will cost you money in a tort like this where proximity-verification volume can get heavy fast.

How MTAA Runs EtO Campaigns

At MTAA, we have managed over $250 million in Facebook ad spend for more than 600 plaintiff law firms across more than 100 torts, and geographic precision torts like EtO are exactly where our campaign architecture is built to perform. We build exposure-zone audiences specific to each active facility, run creative that incorporates the relevant verdict and settlement history, and give our firm clients full transparency on where every dollar goes. Our model is cost-plus, ad spend plus a 15% agency fee, no hidden margins, no inflated media buys.

For EtO specifically, we manage the geofencing parameters, the creative testing across multiple carcinogen-framing angles, and the lead delivery into your intake system. We do not run one generic EtO campaign and push it nationally. We build separate targeting for Waukegan, for the Covington and Atlanta geography, and for emerging locations like Laredo. That specificity is what keeps your cost-per-signed-case competitive as the market matures.

The Bottom Line on Ethylene Oxide as a Case-Acquisition Investment

The Kamuda verdict and the $408M Sterigenics settlement are not the end of EtO litigation. They are the foundation on which the next phase is being built. Medline, Becton Dickinson, and STERIS are real defendants with real exposure, and the science and regulatory record supporting these cases is as strong as anything in the mass tort space. Ethylene oxide mass tort marketing at this stage still offers the geography-concentrated, pre-saturation acquisition economics that smart plaintiff firms look for when evaluating a new investment. The firms that build their intake pipelines now, before Medline and BD trials create the next pricing wave, will be the ones with the best-signed-case economics when those settlements get negotiated. Waiting is an option, but it is the more expensive one.